Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 204

The DOI matches its Crossref record.

Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology Group

Open access
Leavey, Patrick J., Mascarenhas, Leo, Marina, Neyssa, Chen, Zhengjia, Krailo, Mark, Miser, James, Brown, Ken, Tarbell, Nancy, Bernstein, Mark L., Granowetter, Linda, Gebhardt, Mark, Grier, Holcombe E.·2008·Pediatric Blood & Cancer

Abstract

Background: The prognosis for patients with recurrent Ewing sarcoma (EWS) is very poor with 5‐year survival of 13%. Methods: To evaluate prognostic factors for these patients we studied patients initially treated on the multi‐institutional study INT0091. Results: Two hundred sixty‐two patients experienced disease recurrence. The median time to first recurrence was 1.3 years (0–7.4 years), 1.4 years (0–7.4 years) for patients with initially localized disease and 1 year (0–6 years) for patients with initially metastatic disease. Time to first recurrence from date of initial diagnosis was a predictor of post‐recurrence survival ( P < 0.0001). Twenty‐one percent of patients, with recurrent or progressive disease ≥2 years from initial diagnosis, had an estimated 5‐year survival of 30% (vs. 7% estimated 5‐year survival with an earlier recurrence). No statistical difference was detected between patients whose disease recurred <1 year and between 1 and 2 years from initial diagnosis. A stepwise relative risk model and backwards stepwise regression was used to explore factors significantly associated with risk for post‐recurrence death. Significant risk factors for death after recurrence included recurrence at combined local and distant sites, elevated LDH at initial diagnosis and initial recurrence less than 2 years after diagnosis. Isolated pulmonary recurrence was not predictive of survival after recurrence. Conclusion: Patients with a longer disease control interval represent the subset of patients most likely to survive following recurrence of EWS. All patients with recurrence would benefit from collaborative trials to investigate new therapeutic options. Pediatr Blood Cancer 2008;51:334–338. © 2008 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pbc.21618

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 204

Metadata

Authors
Leavey, P. J., Mascarenhas, L., Marina, N., Chen, Z., Krailo, M., Miser, J., Brown, K., Tarbell, N., Bernstein, M. L., Granowetter, L., Gebhardt, M., & Grier, H. E.
Venue
Pediatric Blood & Cancer
Publisher
Wiley
Published
2008-05-27
Volume
51
Issue
3
Pages
334-338
ISSN
  • 1545-5009 (ISSN-L)
  • 1545-5017
OpenAlex
W2050780415
Cited by
204
References
0
FWCI
9.18
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology Group. https://app.cochat.ai/papers/10.1002/pbc.21618
The paper
Leavey, P. J., Mascarenhas, L., Marina, N., Chen, Z., Krailo, M., Miser, J., Brown, K., Tarbell, N., Bernstein, M. L., Granowetter, L., Gebhardt, M., & Grier, H. E. (2008). Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi‐modality therapy: A report from the Children's Oncology Group. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.21618

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.